Merck board approves sale of life sciences unit
The board of directors of Merck has approved the sale of Merck India's life science and analytics business (excluding bulk drugs) to Merck Specialities, a 100% subsidiary of Merck KGaA, Germany, for Rs 99.20 crore (€18.5m).
The board of directors of Merck has approved the sale of Merck India's life science and analytics business (excluding bulk drugs) to Merck Specialities, a 100% subsidiary of Merck KGaA, Germany, for Rs 99.20 crore (€18.5m).
A release issued by Merck to the Bombay Stock Exchange stated that: 'The deal is inclusive of the value of intangibles, fixed and net current assets, and the consideration [sale price] would be suitably adjusted to represent any change in asset/net current value on the date of transaction'.
The sale is now subject to the approval of company shareholders, which will be sought through a postal ballot.